Keyword results: trial

MPL
MPL
PREMIUM CONTENT

The 15 February fraud trial in the USA - another red flag for AIM sewer sinner Mercantile Ports & Logistics

Let us be clear, Mercantile Ports & Logistics (MPL) is not on trial itself.But none the less this looming $300 million fraud trial is another red flag for this perennial AIM uber dog.

Subscribe to ShareProphets to access Premium Content

When related parties are dumping shares at a 75% loss in 4 months you know you should panic – ref MySquar

On 23rd October as oily and unpleasant PR man Piers Pottinger, now the face of the fraud MySquar (MYSQ) as its chairman oozed up to do a paid for share pump interview with Proactive it was announced that Mypay Limited, a related party thanks to links to the criminal family of ex CEO Erik Schaer, had sold shares so it no longer had a notifiable interest. A week later the company did a bailout placing at just 0.35p. It gets worse.

PREMIUM CONTENT

Scancell – FDA throws a spanner into the works//but!

AIM-listed immunotherapy cancer specialist Scancell (SCLP) announced last week that the FDA had posed a few questions regarding its application to run a Phase II combination trial for its SCIB-1 skin cancer compound alongside a checkpoint inhibitor. The market saw this as bad news, and marked the shares down heavily – but I’m not so sure it is all that serious.

Subscribe to ShareProphets to access Premium Content
Bearcast
PREMIUM CONTENT

Tom Winnifrith Bearcast: Led badly astray by Evil Banksta and remoaniac Brexit loathing loon Jonathan Price

Both men attended last night's UK Investor presentation and then plied me with drinks after the event and then at a pub. I rarely drink anything these days and I reacted very badly. God knows how I made the plane but, in the end, I did and woke up in Kalamata. A bit on last night and on Greece and then I look at Telit (TCM), Online Blockchain (OBC) where Clem Chambers' spoofing seems to be having less and less effect and finally the fraud MySquar (MYSQ). It is day two of the trial it wont tell you about.

Subscribe to ShareProphets to access Premium Content

Scancell – things seem to be picking up for this awful share tip

I admit it: this has been a very poor tip, dating way back to the ShareProphets Christmas/New Year tipfest at the end of 2014 when I offered AIM-listed Scancell (SCLP) at 31.75p. Much of what I was looking for came to pass  - apart, that is, from an offer for the company or one of its cancer-busting platforms. And a few things went wrong.

TCM
TCM

Telit - no news = bad news?

The poodles of the PR community, that is to say the deadwood press, were briefed that Telit Communications (TCM) would by Friday have completed the review of whether is CEO was charged with fraud in 1991 but did a runner pre trial. Telit did not deny the allegations we broke as companies invariably do, at first, when exposed. Anyhow it is now Friday.

AZN
AZN

AstraZeneca May Rise If New Drug Launches Come off

One of the big pharmaceuticals which I think will prosper on the misfortunes of millions of people is AstraZeneca (AZN). This is not to say that the company is exploitative. Quite the opposite - its scientists are only trying to help.

Scancell – drug supply problems and a bet with the Sheriff

AIM-listed cancer-buster Scancell (SCLP) announced on Friday that its seven-year-old supply of SCIB-1 vaccine trial doses has had to be withdrawn as the product is no longer within the original specification: it has degraded. The formal trial ended last year, but eight patients elected to continue the treatment which has had to come to an abrupt halt until a new batch is manufactured (about 9-12 months). Bad news, but perhaps not as bad as it might seem.

Afriag - Yusuf Kajee fraud trial moved to Pretoria next week

Since he is in Dubai right now, Yusuf Kajee of Afriag (AFRI) may not have been told that the venue of his fraud trial on 20 January has been moved. I'm always happy to help the old smearer out so...

Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Complete Coverage

Recent Comments

|